Butterfly Network (BFLY) Q1 2026 earnings review
Embedded Strategy Scales as Margins Hit Record Highs
Butterfly Network delivered a strong 26Q1, with revenue growing 25% YoY to $26.5M and gross margins expanding to a record 68.9%. The narrative pivot from a hardware-only point-of-care ultrasound (POCUS) maker to a semiconductor licensing platform ('Butterfly Embedded') is now visibly impacting the bottom line. Software and services revenue surged 68% YoY, primarily driven by embedded partnerships like the Midjourney co-development deal. While the company achieved its first-ever positive operating cash flow last quarter (25Q4), cash burn reversed in Q1, highlighting the inherent lumpiness of large enterprise and licensing deals. With reaffirmed FY26 guidance projecting 20-24% growth, the foundational business model transition appears to be accelerating.
🐂 Bull Case
The Butterfly Embedded licensing model is driving high-margin revenue growth. Software and other services grew 68% YoY, pushing overall gross margins to nearly 69% and validating the 'Intel Inside' strategy.
The FDA clearance of the Gestational Age AI tool and the integration of Compass AI strengthen Butterfly's competitive moat, transforming devices from simple imagers into intelligent diagnostic assistants.
🐻 Bear Case
Despite achieving positive operating cash flow in 25Q4, the company burned $13.9M in operating cash in 26Q1 (worse than the $11.7M burned in 25Q1), underscoring reliance on lumpy milestone payments and seasonal working capital pressure.
Operating expenses rose slightly YoY to $32.2M, with management citing increased headcount and professional services to support growth. Controlling cost growth is essential to reach breakeven.
⚖️ Verdict: 🟢
Bullish. The strategic shift toward semiconductor licensing and software (Butterfly Embedded) is successfully decoupling revenue growth from pure hardware volume, leading to structural margin improvements. If they can smooth out cash collections, the path to profitability is clear.
Key Themes
Butterfly Embedded Powers High-Margin Software Surge
The strategic pivot to license Butterfly's 'ultrasound-on-chip' technology is accelerating. Software and other services revenue exploded 68% YoY to $11.9M in 26Q1. Management explicitly attributed this to the Butterfly Embedded partnerships, specifically highlighting the Midjourney co-development deal. This segment shift is transforming the margin profile, acting as a powerful growth driver independent of traditional hospital capital expenditure cycles.
Gross Margins Approach 70%
Gross margin expanded aggressively to 68.9% in 26Q1, up from 63.0% a year ago. This was driven directly by the favorable mix shift toward high-margin licensing revenue and a reduction in historical software amortization costs. Furthermore, favorable product mix shifts toward the higher-priced iQ3 probes supported both U.S. and International margins.
Operating Cash Flow Reverses to Negative
After celebrating a milestone of positive $6.3M operating cash flow in 25Q4, the trend reversed sharply in 26Q1 with cash used in operating activities totaling $13.9M. This represents a deceleration compared to the $11.7M used in the same quarter last year. The volatility highlights the lumpy nature of enterprise software deals and milestone payments in the new Embedded model, requiring close monitoring of working capital efficiency.
FDA Clearances and AI Innovation Propel Ecosystem
Butterfly continues to rapidly build out its AI moat. The company received FDA clearance for its fully automated Gestational Age AI Tool, initiating its rollout across U.S. and global markets. Meanwhile, development of the next-generation 'Apollo' semiconductor platform advances, promising significantly higher data processing power for advanced on-device AI. The Butterfly Garden ecosystem also expanded to 30 partners.
Home & Community Care Nears Commercialization
Management continues to position the Home & Community Care initiative as a major future growth vector. Following successful pilots that reduced hospital readmissions, the company expects to secure its first commercial agreement in H1 2026, targeting an initial statewide deployment in Q3 2026. This represents a transition from a product-sale to a recurring service-based model.
Other KPIs
Accelerating. Grew 23% YoY, bouncing back from a 6% decline observed in 25Q4. The recovery was largely driven by increased sales to distribution partners and the continued rollout of the higher-priced iQ3 probe in high-growth regions like Brazil.
Stable. Up just 1% YoY from $31.8M. However, excluding stock-based compensation, cash operating expenses rose from $24.9M to $26.2M, reflecting increased headcount to support the Embedded business and higher professional service fees.
Stable. Down from $150.5M at the end of 2025, but provides a very comfortable liquidity runway given the guided Adjusted EBITDA loss of $21M-$25M for the full year. The company's capitalization is secure for the medium term.
Guidance
Stable growth. At the midpoint ($29.0M), this implies approximately 24% YoY growth, matching the Q1 trajectory. This suggests management expects the momentum from the Embedded segment and iQ3 sales to continue smoothly into the next quarter.
Reaffirmed. Represents approximately 20% to 24% annual growth. Maintaining the annual guide following a strong Q1 beat indicates management's confidence that the large Q4 2025 growth spike wasn't a one-off, but rather the start of a sustained higher-growth phase driven by software and licensing.
Reaffirmed. Implies a significant improvement from the FY25 adjusted EBITDA loss (which was roughly in the mid-$30M range). The Q1 loss of $6.1M tracks perfectly in line with achieving this annual target, pointing to strong cost control combined with high-margin revenue growth.
Key Questions
Embedded Licensing Cadence
Software and services revenue surged in Q1, largely driven by Embedded licensing. How lumpy is this revenue stream? Should we expect sequential growth in this line item, or is it heavily dependent on milestone completions from partners like Midjourney?
Operating Cash Flow Reversal
After achieving positive OCF in Q4 2025, cash burn reversed to a $13.9M outflow in Q1. Was this strictly driven by seasonal working capital and headcount additions, or are there underlying collection delays in the newer enterprise and licensing contracts?
Gestational Age AI Rollout
With the FDA clearance of the Gestational Age AI tool, how do you expect this to monetize? Is it a driver for new hardware volume, or will it be offered as a premium software add-on for existing enterprise subscribers?
Home Care Commercial Agreement
You noted expectations for a first commercial Home & Community Care agreement in H1 2026. What are the primary remaining hurdles to signing this contract, and how will revenue recognition be structured once statewide deployment begins in Q3?